Each brain was fixed in formalin for at least 2 weeks, cut into 2- to 3-cm-thick blocks and placed in increasing gradients of sucrose (10%–40%) for cryoprotection. Small blocks from various cortical and subcortical regions were embedded in paraffin, cut at a thickness of 5 µm, and used for pathological diagnosis and for qualitative comparison of TDP-43 inclusions and pre-inclusions between PPA and controls participants. For pathological diagnosis, standard staining protocols, including staining for phosphorylated tau, amyloid-β, α-synuclein, and TDP-43, were employed. All brains were examined for gross and microscopic pathology. Brains of cognitively normal participants were free of pathology except for age-appropriate changes, including low densities and restricted distribution of plaques and tangles. Brains of PPA cases were diagnosed with FTLD-TDP type A pathology or type B pathology (Table 1). FTLD-TDP type A is characterized by many NCIs and short DNs, predominantly in layer 2, while type B consists of moderate NCIs and few DNs throughout all cell layers (17). In addition to the primary TDP proteinopathy, some of the PPA brains contained secondary pathologies. These included ALS-type motor neuron loss (participants 3 and 4, Table 1), mild vascular changes (participants 1 and 3), cerebellar vermis and mammillary body atrophy (participant 1), hippocampal sclerosis, and brainstem Lewy bodies (participant 2).
For determination of pre-inclusion types, distribution and quantitation, whole hemisphere blocks from brains of PPA participants containing regions of interest (ROIs) were cut in the coronal plane at 40-µm thickness on a freezing microtome (Leica SM2010R, Nussloch, Germany). Every 1 in 24 sections was immunohistochemically stained using the avidin-biotin peroxidase (ABC) method, with an antibody against TDP-43 phosphorylated at serine residues 409/410 (pS409/410-2, rabbit polyclonal, 1:3000, CosmoBio, Carlsbad, CA) to visualize inclusions and pre-inclusions. All sections were counterstained with 0.05% Cresyl violet to aid in subcellular localization of the TDP-43 inclusions in neurons.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.